Canadian Court Upholds Lipitor In Crystal Form

Law360, New York (September 13, 2007, 12:00 AM EDT) -- A federal court in Canada has ruled that Pfizer Inc.’s patent covering the key ingredient in Lipitor would be infringed by Ranbaxy Laboratories Ltd.’s method for developing a generic copy of the cholesterol-lowering drug.

Pfizer, the world’s biggest pharmaceutical company, said Wednesday that the Canadian Federal Court in Toronto barred the Indian generics maker from marketing and selling its generic version of a crystalline form of atorvastatin, the active component in Lipitor, until the Canadian patent expires in July 2016.

However, the court found that Ranbaxy’s...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.